Broker Research

We take Punjab National Bank (PNB) out from Under Review and assign an Accumulate rating since (1) growth remains an issue for the bank even though (2) asset quality issues are largely behind the bank.
Sept. 19, 2018, 11:12 a.m.

The stock has been fuelled by outstanding Q1 numbers. Microfinance in today's world has great potential and is possibly one of the next great innovation hub. Ujjivan could turn out to be a POWER ELITE Stock during the course of time.
Sept. 18, 2018, 11:17 p.m.
Author : Rudra Shares And Stock Brokers | Publisher:

The demand for medium and heavy commercial vehicles (MHCVs) has remained strong after the government’s announcement of new axle load norms in July 2018.
Sept. 18, 2018, 11:29 a.m.

Another major step as part of ongoing banking reforms; to pave way for further consolidation! In yet another unexpected move, the Indian government announced the amalgamation of three public sector lenders – Bank of Baroda, Dena Bank and Vijaya Bank.
Sept. 18, 2018, 11:26 a.m.

With the Indian economy gaining momentum, the management expects the consumer durable industry to sustain its healthy growth rate. The size of the industry is likely to double in the next five years from the current level of Rs400bn (share of urban market is 65%).
Sept. 18, 2018, 11:12 a.m.
Author : Nirmal Bang | Publisher:

Piramal Enterprises Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 53,501.22 crores. The stock has been reporting good set of numbers since the last few quarters.
Sept. 18, 2018, 11:10 a.m.

Operational performance at GFL has improved robustly with EBITDA margins at 28.2% in FY18 (21.0% in FY17) resulting in RoCE rising to 13.1% in FY18 (8.2% in FY17).
Sept. 17, 2018, 12:17 p.m.
Author : Way2wealth | Publisher:

In our view, experienced management team, strong profitability trends, improving return profile coupled with change in business mix more towards retail – all these factors put together would drive re-rating in the stock.
Sept. 17, 2018, 11:53 a.m.
Author : LKP Securities | Publisher:

Sun Pharmaceutical Industries (SPIL) has received the US Food and Drug Administration or USFDA’s approval for Xelpros - a novel drug formulation of Xalatan (latanoprost) - the most widely prescribed treatment for Glaucoma.
Sept. 17, 2018, 11:29 a.m.

2QFY19 has seen stable market demand, continuing through 1QFY19. Rural continues to grow ahead of urban (but has still not accelerated to the pace seen a few years ago vis-à-vis urban growth).
Sept. 17, 2018, 11:25 a.m.